New prostate cancer drug aims to block hormones and slow disease
NCT ID NCT07457164
First seen Mar 20, 2026 · Last updated May 18, 2026 · Updated 7 times
Summary
This study tests a new drug called teverelix DP in 40 men with advanced prostate cancer. The goal is to see if it can safely lower testosterone to castrate levels, which can help control the cancer. Participants receive injections on the first day and then every six weeks. The results will help plan a larger future study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.